Lytix Q4 2023: All Eyes on Verrica’s Phase II - Redeye

Lytix's partner Verrica fully recruited its phase II study in basal cell carcinoma in January, with a topline readout expect in H1 2024. This will be a major catalyst that can change the investment case. Lytix will focus the future development of LTX-315 on the neoadjuvant instead of refractory setting, which increases its sales potential, but will also mean a longer time to the market.

Länk till analysen i sin helhet: https://www.redeye.se/research/987383/lytix-q4-2023-all-eyes-on-verricas-phase-ii?utm_source=finwire&utm_medium=RSS